Cladribine and Natalizumab for Relapsing-Remitting Multiple Sclerosis

Details

Files

Project Status:

Active

Project Line:

Reimbursement Review

Project Sub Line:

Streamlined Drug Class Review

Project Number:

TS0004-000

Multiple sclerosis (MS) is a chronic autoimmune disease with the following clinical manifestations: demyelination, inflammation, neuronal loss, and gliosis (scarring). Relapsing-remitting multiple sclerosis (RRMS) is the most common type of the disease, with a subgroup of patients who have a more aggressive disease course — manifesting with a rapid accumulation of physical or cognitive deficits — which is referred to as highly active RR MS.

Public drug programs have requested a review to assess the comparative efficacy and harms of cladribine and natalizumab for first-line treatment of highly active RRMS to inform reimbursement of these 2 drugs.

Note that considering the input we received on the project scope, and in consultation with the clinical experts, the review protocol was amended after posting the project scope to incorporate the broader RRMS population.

Call for feedback

Call for feedback : Feb 20, 2025